Medicus Pharma Submits Optimized Teverelix Registrational Protocol to FDA
PHILADELPHIA — September 29, 2026 Medicus Pharma Ltd. announced that it has submitted an optimized seamless Phase 2b/3 registration-intent...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease solid tumors targeted therapy
PHILADELPHIA — September 29, 2026 Medicus Pharma Ltd. announced that it has submitted an optimized seamless Phase 2b/3 registration-intent...
COPENHAGEN, Denmark — September 22, 2026 Zealand Pharma announced the initiation of the global registrational Phase 3a ZUPREME program...
MILLBRAE, Calif., August 11, 2026 Eikon Therapeutics announced the selection of a 0.60 mg/m² dose of EIK1001 for patients...
PARIS, Aug. 4, 2026 Sanofi announced that the European Commission (EC) has approved an expanded indication for MenQuadfi® (Meningococcal...
BRISBANE, Calif., Aug. 4, 2026 Nurix Therapeutics, Inc. announced the enrollment of the first patient in the registrational Phase...
GAITHERSBURG, Md., Aug. 3, 2026 Altimmune, Inc. has initiated patient enrollment in the global PERFORMA Phase 3 registrational trial...
NORWOOD, Mass., July 28, 2026 Corbus Pharmaceuticals Holdings, Inc. has received U.S. Food and Drug Administration (FDA) clearance to...
